Av
Förra veckan gick Allenex storägare, Mohammed Al-Amoudis och Sven-Olof Johanssons, erbjudande ut om att köpa upp de övriga aktieägarnas innehav. Erbjudandet accepterades av aktieägare till totalt elva miljoner aktier, vilket motsvarar 9,3 procent av samtliga aktier i Allenex. Detta innebär att storägarna nu totalt äger 77 procent av aktierna i Allenex. För att tvinga in de sista aktierna, och på så vis bli helägare till bolaget, hade storägarna behövt ha 90 procent av aktierna.
Vid Allenex senaste nyemission hoppade storägarna, tillika garanterna, in och köpte upp de aktier som inte hade tecknats under emissionsperioden. Detta gjorde att deras aktieinnehav översteg 30 procent av ägarandelen i bolaget och de hamnade under budplikt. I slutet av november lade de båda storägarna, affärsmannen Mohammed Al-Amoudi och fastighetsbolaget Fastpartner med Sven-Olof Johansson i spetsen, ett bud på bolaget.
Mohammed Al-Amoudi och Sven-Olof Johansson erbjöd, genom sitt gemensamma bolag Xenella, Allenex övriga aktieägare 1,50 kronor per aktie. Vid tidpunkten för erbjudandet låg aktiekursen på omkring 1,49 kronor aktien. I slutet av december gick Allenex styrelse ut och avrådde aktieägarna från att acceptera erbjudandet. Detta på inrådan av den finansiella rådgivaren KPMG som ansåg att aktien var värd mer.
Störst aktieägare i dag är Mohammed Al Amoudi med ett innehav som uppgår till 36,3 procent av bolagets aktier. Näst störst ägare är Sven-Olof Johansson som, genom sitt bolag Fastpartner, har ett aktieinnehav på 32,3 procent. Efter erbjudandet gått ut kvalar Xenella in som tredje största aktieägare med ett innehav på 9,3 procent.
Vid Allenex senaste nyemission hoppade storägarna, tillika garanterna, in och köpte upp de aktier som inte hade tecknats under emissionsperioden. Detta gjorde att deras aktieinnehav översteg 30 procent av ägarandelen i bolaget och de hamnade under budplikt. I slutet av november lade de båda storägarna, affärsmannen Mohammed Al-Amoudi och fastighetsbolaget Fastpartner med Sven-Olof Johansson i spetsen, ett bud på bolaget.
Mohammed Al-Amoudi och Sven-Olof Johansson erbjöd, genom sitt gemensamma bolag Xenella, Allenex övriga aktieägare 1,50 kronor per aktie. Vid tidpunkten för erbjudandet låg aktiekursen på omkring 1,49 kronor aktien. I slutet av december gick Allenex styrelse ut och avrådde aktieägarna från att acceptera erbjudandet. Detta på inrådan av den finansiella rådgivaren KPMG som ansåg att aktien var värd mer.
Störst aktieägare i dag är Mohammed Al Amoudi med ett innehav som uppgår till 36,3 procent av bolagets aktier. Näst störst ägare är Sven-Olof Johansson som, genom sitt bolag Fastpartner, har ett aktieinnehav på 32,3 procent. Efter erbjudandet gått ut kvalar Xenella in som tredje största aktieägare med ett innehav på 9,3 procent.
"The PolyPeptide Group is a world class manufacturer of peptide active pharmaceutical ingredients." 
"Medivir is a specialty pharmaceutical company with unique positioning on the Nordic market and our goal is become a profitable company in high growth" 
"To be the most attractive node and business platform in the Nordic countries for new and innovative Life Science companies" 
"To develop innovative and effective pharmaceuticals within autoimmune/ inflammatory diseases and cancer where major medical need exists" 
"Your work is important to us, we are committed to your success.
Innovative tools? Please download the Promega app." 
"Novel products for CVD treatment and prevention." 
"We are entirely devoted to luminescence technology." 
"Our vision is to become one of the top 10 global providers of scientific instruments; we will get there by striving for market leadership in our respective product and application niches."
" 
"Mercodia has been a supplier of reliable assays since 1991" 
"Discover your possibilities in one of Europe´s most productive life science regions. Welcome to Stockholm-Uppsala."
" 
"Anton Paar is a product and service leader in the field of scientific instruments. We deliver uncompromised quality in everything we do." 
"To supply Swedish and Danish laboratories with laboratory equipment and furniture of highest quality and offer service on all delivered products." 
"Our services in ligand-based and structure-based drug design is a cost-efficient alternative for smaller pharmaceutical companies" 
"Our aim is to be the best drug development partner to the biotechnology and pharmaceutical industry no matter where you are based." 
"To adapt Competent Authorities´ requirements into opportunities is not just an artform - today it´s a business necessity." 
"We have a unique technological platform, built around 5HT-receptor antagonism, for the treatment of inflammation and pain"." 
"PCG - a professional full service CRO for your clinical trials.
Powered by Viedoc, globally trusted eCRF, keeping trials within budget and timelines" 
"To be acknowledged as the Best-in-Class provider of pharmaceutical development and manufacturing services by customers, employees & other stakeholders" 
"Dilafor is developing new products in the field of obstetrics, to provide an effective solution to the challenge of dystocia or protracted labor"
" 
"Together with Zacco our clients achieve their business goals through the management of their intellectual property." 
"Your global partner of pharmaceutical service and cGMP manufacturing" 
"We are recognized as a flexible partner with short decision and lead times plus a proven record for the highest quality and cost efficiency." 
"We help our clients create significant business value through scientific expertise." 
"We promise to go the extra mile every day to ensure you receive the highest level of service and value with each shipment you entrust to us." 
"Uppsala BIO is a life science pathfinder. We build ways to make life science flourish, in cooperation with industry, academia, society and healthcare." 
"VWR is a global laboratory distributor of chemicals, life science products, consumables, equipment, instruments, furniture, e-commerce and services" 
"Best in class companies see the value of optimising their business by having an effective strategy for information management and documentation." 
"Our goal is to invest in innovations and develop new unique pharmaceuticals" 
"Our products enable an increased number of transplants leading to substantial cost savings for society and increased quality of life for patients." 
"To become an internationally leading dental company with innovative, proprietary products of high therapeutic and commercial value." 
"With our first class products and our committed and skilled colleagues we guarantee our customers the best support in the market, at no extra charge." 
"We turn medical research into applications for better health and well-being." 
"Our organisation value is to contribute to positioning Scandinavian healthcare and research in absolute world class." 
"Innovation takes place when biology meets engineering; ICT is an enabler to solve the needs for increased functionality and reduced cost in Life Science" 
"We are making it more attractive for companies to invest in innovation with reduced corporation tax on profits from patents to 10%." 
"We aim to be the pioneering benchmark in user-friendly software experience in combination with the highest level of quality." 
"Our reliability, customer service, global network and integrated technology make World Courier service truly "A service no one else can deliver"." 
"As a full service CRO with offices in all Nordic countries we can provide our customer with professional support throughout the clinical research." 
"TFS is today the leading European development partner for biopharmaceutical companies in their global clinical development process." 
"APL provides high-quality services to Life Science. We are a Dedicated Partner from Discovery to Market." 
"Allenex is a life science company that develops, manufactures, markets and sells high quality products for the transplantation market." 
"We offer effective staffing solutions provided by specialists, we understand a company’s specific needs and we know where to find the best talent." 
